Completed PHASE2 INTERVENTIONAL 1-arm NCT00054132

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

A Phase II Study of OSI-774 in Combination With Bevacizumab in Patients With Stage IV Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Breast Carcinoma Stage IV Breast Cancer

Interventions Bevacizumab Erlotinib Hydrochloride Laboratory Biomarker Analysis

Updated 7 times since 2017 Last updated: Jun 23, 2017 Started: Dec 31, 2002 Primary completion: Apr 30, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Recurrent Breast Carcinoma and Stage IV Breast Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Aug 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Aug 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States
• San Francisco, United States